Drug Trial Radar · NCT05983445
Safety & Efffficacy of Genakumab in Patients With Frequent Flares
Last checked: Nov 20, 2026Latest source record: Dec 18, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
313
Actual
Start
Jan 11, 2023
Primary completion
Apr 3, 2024
Study completion Apr 3, 2024
Sponsor
- Lead sponsor
- Changchun GeneScience Pharmaceutical Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Aug 9, 2023
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the efficacy and safety of Genakumab Injection in patients with Gouty Arthritis (GA).
Conditions
- Acute Gout Arthritis
Interventions
genakumabDrug
200mg s.c.
placebo for DiprospanDrug
i.m.
placebo for genakumabDrug
s.c.
DiprospanDrug
7mg i.m.
Primary outcomes
What the sponsor says the trial is designed to measure.
- The change in the gout pain intensity in the target joint measured by VASTime frame: 72 hours post-dose
- Time to first new flareTime frame: 12 weeks
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Fudan University Affiliated Huashan Hospital
Shanghai, Shanghai Municipality, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.